San Diego, CA -- (SBWIRE) -- 02/06/2017 -- An investor, who purchased shares of Regulus Therapeutics Inc (NASDAQ:RGLS), filed a lawsuit in California over alleged violations Securities Laws by Regulus Therapeutics Inc

Investors who purchased shares of Regulus Therapeutics Inc (NASDAQ:RGLS) have certain options and for certain investors are short and strict deadlines running. Deadline: April 3, 2017. NASDAQ:RGLS investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The plaintiff claims that between January 21, 2016 and June 27, 2016 the Defendants made false and/or misleading statements and/or failed to disclose that patients treated with RG-101 were at increased risk of contracting jaundice, that consequently, the Company had overstated RG-101's approval prospects and/or commercial viability, and that as a result of the foregoing, Regulus's public statements were materially false and misleading at all relevant times.

On June 27, 2016, Regulus Therapeutics Inc announced during aftermarket hours that it received verbal notice from the U.S. Food and Drug Administration ("FDA") that the FDA had placed the Regulus Therapeutics' investigational new drug for the treatment of chronic hepatitis C virus infection on clinical hold after a second serious adverse event of jaundice was reported.

Shares of Regulus Therapeutics Inc declined on June 28, 2016 to as low as $2.44 per share.

Those who purchased shares of Regulus Therapeutics Inc have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com